Data as of Apr 17
| +0.45 / +4.96%|
The 7 analysts offering 12-month price forecasts for Cytokinetics Inc have a median target of 23.00, with a high estimate of 26.00 and a low estimate of 18.00. The median estimate represents a +141.60% increase from the last price of 9.52.
The current consensus among 8 polled investment analysts is to Buy stock in Cytokinetics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.